Want to see JP:4594 full AI Analyst Report?
Top Page
BrightPath Biotherapeutics Co.Ltd.
(4594)
Select Model
Select Model
Rating:46Neutral
Price Target:
¥51.00
▲(6.25% Upside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance—highly volatile/collapsing revenue, ongoing sizable losses, and persistent free-cash-flow burn—despite a low-leverage balance sheet. Technicals provide some offset with improved short-term momentum, but longer-term trend indicators remain negative. Valuation is also unfavorable/unclear due to unprofitability and no stated dividend yield.
Positive Factors
Low leverage
Very low leverage reduces refinancing risk and limits interest-related pressure. This gives BrightPath more financial flexibility than a similarly unprofitable biotechnology company, although continued losses could still require external funding.
Negative Factors
Severe revenue volatility
The sharp revenue decline and prior spike indicate weak and uneven commercial traction, potentially reflecting dependence on milestones or other irregular income. This makes forecasting difficult and limits confidence in a durable revenue base.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage reduces refinancing risk and limits interest-related pressure. This gives BrightPath more financial flexibility than a similarly unprofitable biotechnology company, although continued losses could still require external funding.
Read all positive factors
BrightPath Biotherapeutics Co.Ltd. (4594) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.50B
Dividend YieldN/A
Average Volume (3M)2.78M
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth-94.55%
EPS Growth-6.51%
CountryJP
Employees42
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.97
Shares Outstanding138,891,300
10 Day Avg. Volume4,086,650
30 Day Avg. Volume2,782,203
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.25
Price to Sales (P/S)91636.06
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BrightPath Biotherapeutics Co.Ltd. Business Overview & Revenue Model
Company Description
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies f...
How the Company Makes Money
null...
BrightPath Biotherapeutics Co.Ltd. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 84.00K | 1.13M | 72.00K | 5.28M | 15.41M |
| Gross Profit | 55.00K | 1.10M | -341.00K | -13.33M | -23.03M |
| EBITDA | -1.30B | -1.15B | -1.17B | -1.47B | -1.45B |
| Net Income | -1.30B | -1.15B | -1.17B | -1.49B | -1.48B |
Balance Sheet | |||||
| Total Assets | 2.60B | 1.12B | 1.23B | 1.70B | 2.77B |
| Cash, Cash Equivalents and Short-Term Investments | 2.16B | 810.47M | 1.06B | 1.53B | 2.31B |
| Total Debt | 0.00 | 25.00M | 112.50M | 0.00 | 87.50M |
| Total Liabilities | 236.41M | 195.62M | 251.27M | 133.91M | 239.73M |
| Stockholders Equity | 2.37B | 924.99M | 978.99M | 1.57B | 2.53B |
Cash Flow | |||||
| Free Cash Flow | -1.37B | -1.25B | -1.16B | -1.21B | -1.53B |
| Operating Cash Flow | -1.37B | -1.25B | -1.16B | -1.20B | -1.51B |
| Investing Cash Flow | -1.93M | -1.37M | -7.65M | -1.76M | -17.57M |
| Financing Cash Flow | 2.71B | 1.00B | 690.96M | 432.10M | 569.23M |
BrightPath Biotherapeutics Co.Ltd. Technical Analysis
Positive
48.00
Price Trends
49.08
Positive
52.32
Positive
56.91
Negative
Market Momentum
1.35
Negative
59.79
Neutral
61.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4594, the sentiment is Positive. The current price of 48 is below the 20-day moving average (MA) of 51.75, below the 50-day MA of 49.08, and below the 200-day MA of 56.91, indicating a neutral trend. The MACD of 1.35 indicates Negative momentum. The RSI at 59.79 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4594.
BrightPath Biotherapeutics Co.Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥7.79B | 52.16 | ― | ― | 4.85% | -40.57% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ¥22.38B | -11.91 | ― | ― | ― | 6.10% | |
47 Neutral | ¥41.31B | 61.69 | ― | ― | -47.32% | ― | |
46 Neutral | ¥7.50B | -4.22 | ― | ― | -94.55% | -6.51% | |
46 Neutral | ¥6.81B | 96.35 | ― | 1.24% | -7.13% | ― | |
42 Neutral | ¥9.30B | -8.15 | ― | ― | -56.16% | 3.12% |
* General Sector Average
JP:4594
BrightPath Biotherapeutics Co.Ltd.
54.00
-38.00
-41.30%
JP:4593
Healios KK
306.00
-237.00
-43.65%
JP:4599
StemRIM Inc.
357.00
49.00
15.91%
JP:4880
CellSource Co., Ltd.
343.00
-254.00
-42.55%
JP:7096
StemCell Institute
760.00
-210.00
-21.65%
JP:7776
CellSeed Inc.
236.00
-214.00
-47.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.